A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen
{{output}}
Objectives: Using the case study of patisiran and inotersen, we conducted a narrative comparative analysis of the health technology assessment (HTA) agency appraisals of these two first-in-class transthyretin gene silencers, whic... ...
